Clinical laboratory assessment of hepatitis C and HIV coinfected patients according to the antiretroviral therapy received Avaliação clínico-laboratorial de pacientes co-infectados com o vírus da hepatite C e HIV-1 em relação ao tipo de terapia antirretroviral recebida

• Published in: Revista do Instituto de Medicina Tropical de São Paulo
• Main Authors: Roberto M. Carrasco Navarro, Maria Cássia Jacintho Mendes-Correa, Norma de Paula Cavalheiro, Antonio Alci Barone
• Format: Article in Journal/Newspaper
• Language: English
• Published: Universidade de São Paulo (USP) 2005
• Subjects: Coinfection; HIV; HCV; AIDS; HAART; Liver biopsy; Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic; Elevado
• Online Access: https://doi.org/10.1590/S0036-46652005000100003; https://doaj.org/article/e0081ad1e1904ca58b6eb633a9b90026

During the year of 2001, a retrospective, descriptive study in order to determine the influence of the antiretroviral therapy received by 111 HIV-HCV coinfected patients who had undergone at least one liver biopsy was conduced, 74 of them were treated with a protease inhibitor regimen (WPI), and 37 with a non-protease inhibitor regimen (NPI). The main characteristics found were: a young patient population (mean age 41 years old in both groups), composed in most part of male individuals (74.3% WPI and 51.4% NPI) with previous risk factors for both infections (WPI 93.2% and NPI 89.2%). The most significant findings included AIDS-defining disease (WPI 18.9% and NPI 13.5% of the cases), elevated hepatic enzyme levels (WPI: SGOT 52.1 and NPI 53.2), absence of liver disease-related symptoms (16.2% for both groups), average CD4 count > 350 for both groups (WPI 362.2 and NPI 378.1), predominantly low-grade fibrosis in both populations (0-2 in 63.6% of WPI patients and in 80% of NPI patients), with necro-inflammatory activity ranging from 5-7 in 51.3% and 42.9% of WPI patients and NPI patients, respectively. It is suggested a sequential biopsy to better evaluate the evolution of the hepatic disease, according to the HAART regimen received. Durante o ano de 2001, um estudo retrospectivo e descritivo foi efetuado a fim de determinar a influência da terapia antirretroviral recebida por 111 pacientes co-infectados HIV-HCV que tinham se submetido ao menos a uma biopsia hepática. Destes, 74 foram tratados com um regime contendo inibidor da protease (WPI) e 37 com um regime do não contendo inibidor da protease (NPI). As características principais encontradas eram: uma população de pacientes jovem (idade média 41 anos em ambos os grupos), composta na maior parte por indivíduos masculinos (74,3% WPI e 51,4% NPI) com fatores de risco precedentes para ambas as infecções (WPI 93,2% e NPI 89,2%). Os achados mais significativos incluíram doença definidora de AIDS (WPI 18,9% e NPI 13,5% dos casos), nível elevado de enzimas hepáticas ...